My Daughter Died From the Abortion Drug 10 Years Ago Today

Leave a comment

This is from Life News.

These are the stories the Obama Media will not carry.

As it does not promote the pro abortion template.

Obama is worried about the children of Syria being killed.

What about the thousand’s murdered by abortion each day?

The U.S. Supreme Court recently accepted a case Cline v. Oklahoma Coalition for Reproductive Justice, challenging Oklahoma’s regulation of the abortion drug Mifeprex commonly known as mifepristone, RU-486, or The Abortion Pill.​

The case is an appeal by the state of Oklahoma from a ruling by its Supreme Court striking down a 2011 law that requires prescribing physicians to follow the FDA’s protocol for administering the Mifeprex abortion pill regimen using a combination of two drugs; mifepristone and misoprostol.

The Oklahoma law does not ban the use of the Mifeprex regimen, nor does it ban any abortion before or after 49 days gestation. It simply requires that the medical abortion regimen be administered in the way deemed safest by the FDA. The Act imposes no obstacle or undue burden to women seeking access to an abortion.

Monty Patterson’s Participation in the Case

As part of this Supreme Court case, I submitted an “Affidavit of Monty Patterson, father of Holly Patterson” in support of the “Brief of Women and Families Hurt by RU-486.”

My daughter, Holly Patterson, tragically died in 2003, seven days after the initial start of her 7-week-old pregnancy termination from a massive infection known as Clostridium sordellii toxic shock syndrome that was associated with a medically induced abortion.

Planned Parenthood prescribed my teenage daughter an unapproved, off-label RU-486 medical abortion regimen touted to be equally as safe an effective as the FDA protocol. Holly, barely 18-years-old, took advice from her provider and was persuaded to choose their alternative medical abortion regimen.

Holly did not receive accurate and truthful information concerning medical abortion in order to make an informed decision about her safe reproductive healthcare.

Since my daughter’s death, I have researched and studied the risks of mifepristone and misoprostol medical abortion and have built an educational website that discusses and details the facts that reveal significant safety concerns for women who consider an early pregnancy termination.

In the past 13 years, since FDA approval of RU-486, there have been an alarming number of serious health complications and injuries to women, including death.

The FDA has evaluated these injuries and deaths and publicly reported the off-label uses of the Mifeprex regimen has resulted in serious or sometimes fatal adverse events.

Personally, I do not believe any medical abortion pill regimen using mifepristone and misprostol to terminate early pregnancy is safe.

My focus is not to be pulled into the larger national abortion debate that has divided the United States into pro-choice and pro-life camps.

The United States Supreme Court has made it landmark decision on the issue of abortion. Women have certain legal rights to access and reproductive health care choices under the law.

With the legalization of abortion, a woman and her family should therefore be entitled to all the facts and risks to properly make informed decisions that are in their best interest, safety, health and welfare. This includes the choice of medical abortion with the drug regimen of mifepristone and misoprostol.

Abortion providers are promoting the use of unapproved off-label medical abortion regimens that may not have received the same degree of scientific scrutiny as the FDA approved mifepristone protocol. This problem needs to be addressed.

I have made it my focus to help educate women, families, researchers, even health care professionals to become informed of the facts and health risks of medical abortion to terminate an early pregnancy.

Significant issues of concern to me are: What are acceptable medical abortion practices? How are medical abortion providers exposing women to unnecessary health risks to already a potentially dangerous procedure?

The issue of legalized medical abortion should not be in question, but the issues of safe medical abortion protocol(s) and practices remain to be answered.

Off-Label Loopholes and Practices

Special interest groups and abortion providers have been taking advantage of huge loopholes in our drug regulatory system. Once medical abortion was approved by the FDA in 2000 and put on the market, there is absolutely nothing to prevent any abortion provider from using an alternative drug regimen in any manner, in any dose, for any patient he or she chooses. The drug’s labeling contains the indications approved by the FDA and these alternative uses are called “off-label” use of drugs.

Medical Abortion advocates contend that “doctors use drugs off-label all the time!” Organizations like Planned Parenthood are taking matters into their own hands when it comes to the use of medical abortion with mifepristone and misoprostol on their women patients. Sometimes these patients are teenage adolescents as young as 14 years old.

Common off-label usage of drugs in general does not prove it is a good idea, especially where safe medical abortion practices are critical to a woman’s health. Should medical abortion providers continue to promote their off-label prescribing as they continue to gain more confidence in what has been a serious mistake resulting in thousands of injuries and at least 14 deaths?

Medical abortion advocates claim off-label uses are not considered experimental to patients because their regimens have been “demonstrated by scientific research to be safer and more effective.”

Who makes the decisions if the medical abortion industry-sponsored research is sound scientific evidence? Who are these scientific bodies? Is it an organization of professionals trying to protect the special interests of their members?

Medical abortion providers using unapproved off-label regimens represents both a cavalier disregard for the safety of women and a total lack of faith in the U.S. Food and Drug Administration’s drug regulatory system.

Isn’t the whole purpose of FDA approved on-label use to provide assurances to the patient there is sound scientific evidence?

Providers Ignore FDA Public Health Advisories

The argument that the approved FDA protocol is an “old guideline” and considered to be “bad medicine” does not appear to be embraced by FDA officials.

The FDA has published Mifeprex “Public Health Advisories” when women have been seriously injured or suffer fatal consequences as a result of Mifeprex off-label medical abortion practice. These advisories state that the safety and effectiveness of other Mifeprex dosing regimens, including use of oral misoprostol tablets intra-vaginally has not been recognized or accepted by the FDA.

The FDA continues to stand by the Mifeprex protocol they evaluated and publicly remind abortion health care professionals of the approved Mifeprex dosing regimen.

Medical abortion practitioners continue to ignore every FDA Public Health Advisory. They continue to use modified regimens, by increasing the gestational age limit, shortening the process, decreasing their costs, changing the dosing regimen, decreasing physician oversight by allowing women to administer misoprostol at home (instead of at the provider’s clinic) and reducing the number of patient’s return visits back to the clinic. Some practitioners advise their patients to repeat misoprostol dosing to try to improve on abortion success rates.

These practitioners have turned their off-label regimens into  the “Do it Yourself” at home procedure where women are shouldering the responsibility for their own health, safety and well-being.

Making The Case For Safety

Medical abortion rights advocates are trying to make the case that off-label regimens are a safety improvement over the current FDA protocol. They oppose any action where providers may be required to prescribe three-times-more Mifeprex, essential for pregnancy termination, than they think is called for. No matter if it violates FDA approved protocol.

What about the off-label prescribing of the second drug misoprostol?

Is it considered a safety improvement for abortion providers to double the dose of buccal or vaginally administered misoprostol to further induce labor and increase contractions to expel the embryo and placental tissues? Further, additional doses of misoprostol may be prescribed for incomplete abortion complications.

Misoprostol carries its own boxed warnings, but they can’t be found in the Mifeprex drug labeling or the Patient Agreement and Medication Guide. Why aren’t providers informing women about uterine rupture that has been reported when misoprostol is administered to induce labor beyond the eighth week of pregnancy?

Providers have increased medical abortion gestation age limits from 7 weeks to 9 weeks to make it available to more women. Is that another safety improvement?

Mifeprex is being prescribed at a 1/3 reduced dose because medical abortion providers understand the cost benefits of misoprostol over Mifeprex. Mifeprex is expensive but misoprostol is a very cheap and readily available. To increase profits, misoprostol is used by providers as the predominant abortifacient agent in the regimen (not mifepristone) to terminate early pregnancy.

Medical evidence points to the fact that off-label uses of Mifeprex have resulted in more serious adverse health events, including death, than the FDA-approved regimen.

Medical abortion rights advocates claim this action is about punishment and discrimination against women who seek Mifeprex to induce medical abortion. Did the FDA have that in mind when they approved the drug sponsor’s application for distribution and prescribing of Mifeprex?

The off-label prescribing of medical abortion drug regimens has resulted in disastrous health consequences for thousands of women. Every recorded U.S. death, as in the case of Holly Patterson, has been a result of off-label Mifeprex and misoprostol use to terminate early pregnancy.

Medical abortion can be an unpredictable and dangerous alternative, especially when abortion providers choose to ignore and circumvent the FDA approved protocol.

Medical Opinion Or Evidence?

FDA’s approval of mifepristone is supposed to be based on controlled studies and independent analysis of data by qualified doctors and scientists designated to review and monitor clinical medical research.

If abortion researchers and providers believe they have regimens that are “safer and more effective” than the one approved by the FDA in 2000, then they should submit them to the U.S. Food and Drug Administration, along with their unbiased and so-called “evidence-based” studies, for rigorous FDA review and evaluation. Obviously, they haven’t, and don’t intend to do so.

After all, shouldn’t women deserve quality information to ensure the medical community has all of the available facts on which to base medical abortion treatment decisions that aren’t biased, industry-sponsored and motivated by profit and market expansion?

If medical abortion advocates, providers, and their researchers were really looking out for the best interest of women’s reproductive health care, this contentious debate requiring a U.S. Supreme Court decision may have been avoided.




Abortion Drug RU 486 Has Killed Two Million Unborn Children in the U.S.

1 Comment

This is from Life News.

If it isn’t the Kermit Gosnell‘s of the world murdering babies and killing women.

It is now some pill that is murdering babies and hurting and killing women.

Proverbs 6:16-17

King James Version (KJV)

16 These six things doth the Lord hate: yea, seven are an abomination unto him:

17 A proud look, a lying tongue, and hands that shed innocent blood,


The dangerous RU 486 abortion drug has nearly claimed the lives of two million unborn children in the United States since its approval at the end of the Clinton administration.

The Food and Drug Administration, which approved the drug in late 1999, estimated in April 2011 that 1.52 million American women had taken RU-486 to induce an abortion. According to CDC reports, about 16.5 percent of the estimated 1.2 million abortions that take place annually in the United States involve the mifepristone drug, commonly known as RU 486.

In other words, about 198,000 abortions take place each year with the drug, or 16,500 each month, and the RU 486 drug has claimed the lives of approximately 462,000 unborn children in the 28 months since the FDA released its April 2011 estimate — for a total of 1,982,000 abortions. With the Planned Parenthood abortion business pushing increased usage of the mifepristone abortion pill via webcam abortions over the last few years, it’s likely the number of two million abortions involving the RU 486 abortion pill since its approval in the U.S. has already been surpassed.

In addition to the number of unborn children whose lives have been lost to the abortion drug, women have suffered as well, as a Planned Parenthood study admitsat least one woman is seriously injured from the abortion pill daily.

Following its approval during the Clinton administration, the FDA released a report in 2006 that received widespread attention for showing more than 1,100 women had been subjected to “adverse effects” resulting from their taking the abortion drug.

The FDA, with no fanfare, released its April 2011 report showing 14 women in the United States alone have died from using the mifepristone abortion drug and 2,207 women have been injured by it.

Of the women experiencing medical and physical problems resulting from the abortion drug, 612 women required hospitalizations, 339 experienced blood loss significant enough to require a transfusion, 256 experienced infections and 48 women experienced what the FDA labeled as “severe infections.” Given that the RU 486 abortion drug caused sepsis, a potentially lethal infection that resulted in the deaths of women from around the world, the “serious infections” were very likely life-threatening situations.

“Severe infections generally involve death or hospitalization for at least 2-3 days, intravenous antibiotics for at least 24 hours, total antibiotic usage for at least 3 days, and any other physical or clinical findings, laboratory data or surgery that suggest a severe infection,” the FDA report stated.

Women developing infections from usage of the RU 486 abortion drug experienced endometritis (involving the lining of the womb), pelvic inflammatory disease (involving the nearby reproductive organs such as the fallopian tubes or ovaries), and pelvic infections with sepsis (a serious systemic infection that has spread beyond the reproductive organs).

The FDA figures also reveal that abortion businesses like Planned Parenthood are still misusing the abortion drug.

Despite the FDA indicating, “Administration of mifepristone and misoprostol is contraindicated in patients with confirmed or suspected ectopic pregnancy (a pregnancy outside the uterus,” the abortion drug was given to women in 58 cases where they had an ectopic pregnancy at that time.

An FDA panel eventually investigated the deaths and found that the vaginal, rather than oral, use of the abortion drug was likely contributing to the deaths. Planned Parenthood had been going against the FDA guidelines on using the abortion drug and changed its protocols to allow for oral use after women died at their facilities.

In 2012, Chris Gacek, who received a Bachelors of Science in economics from the Wharton School, University of Pennsylvania, a Masters and Ph.D. in political science from Stanford University, and a J.D. from the University of Virginia School of Lawauthored a comprehensive report on mifepristone.

On the unsafe effects of RU 486 for women:

Dr. Ralph Miech, emeritus professor at Brown University’s medical school, has published two peer-reviewed articles describing potentially undesirable effects related to RU-486 and its anti-glucocorticoid properties.[8] First, he believes that RU-486′s blockade of cortisol receptors on bacteria-destroying white blood cells may impede the antibacterial defense mechanism of the innate immune system. Such interference, he hypothesizes, played a significant role in the deaths of at least five North Americans in which there was a post abortion, bacterial invasion of the uterus and subsequent septic shock.[9] Second, prompted by an article describing mifepristone-related adverse events with significant and unexpected levels of hemorrhage, Miech’s second article argues that RU-486 appears to interfere with the body’s ability to control uterine hemorrhage.[10] Such interference, if true, would be a dangerous feature of an abortion procedure that is designed to produce a simulated miscarriage. As will be noted below, the number of hemorrhage/transfusion and serious infection cases revealed by FDA support Miech’s concern about RU-486 and hemorrhage.

Looking at specific cases of the abortion drug hurting women:

FDA’s April 2011 RU-486 Adverse Events Summary states that “[t]he estimated number of women who have used mifepristone in the US through the end of April 2011 is approximately 1.52 million women.” As noted above, FDA calculated that by that date there had been 2,207 adverse event reports submitted to FDA.[25] Prior to a 2006 oversight hearing on RU-486 safety, FDA told Rep. Mark Souder (R-Ind.) that it had received 1,070 AERs.[26] Thus, in the second five years of mifepristone marketing in the United States, the FDA received an additional 1,137 AERs-a total which seems consistent with the first five years.

The April 2011 RU-486 Adverse Events Summary states that there were 612 reports of hospitalization received as of April 30, 2011.

FDA’s April 2011 RU-486 Adverse Events Summary indicates that 339 women “experienced blood loss requiring a transfusion” after taking the RU-486 abortion regimen.

By April 2011 FDA had fifty-eight reports of ectopic pregnancy cases – with two resulting in death – in conjunction with mifepristone-misoprostol use.

In the April 2011 RU-486 Adverse Events Summary FDA associated fourteen American deaths to the use of the mifepristone-misoprostol abortion regimen.

And, according to a study on medical abortion’s safety and effectiveness published in Obstetrics & Gynecology and that Gacek noted, the abortion drug is more dangerous for women than surgical abortions:

“Overall, medical abortion had roughly four times the rate of adverse events than surgical abortion did: 20.0% of women in the medical-abortion group and 5.6% of women in the surgical-abortion group had at least one type of adverse event.  Hemorrhage, as an adverse event, was experienced by 15.6% of medical abortion patients compared with 2.1% for surgical patients. Incomplete abortions were experienced by 6.7% of medical abortion patients while only 1.6% of surgical patients had incomplete abortions. The rate for surgical (re)evacuation of the uterus was 5.9% (medical) versus 1.8% (surgical) for all causes (hemorrhage, infection, incomplete abortion).

%d bloggers like this: